Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Laboratories is supported by a diversified portfolio that is already showing resilience in Nutrition and Diagnostics, where 3Q26 revenue of about $2.3 billion and $1.6 billion, respectively, came in above expectations and underlying demand improved across pediatric, adult, Core Lab, and Cancer Diagnostics. The near-term reset in diabetes and electrophysiology appears driven more by temporary market-access, pricing, and product-transition issues than by end-demand deterioration, while key catalysts such as Libre Duo, a major U.S. formulary win effective in January 2027, and Amulet 360/Volt launches should re-accelerate growth. The planned Nutrition separation by year-end 2027, along with a roughly 60% international sales mix, margin expansion potential, and a valuation near ten-year lows at about 17x 2027 EPS, strengthen the case for improved organic growth, higher profitability, and multiple expansion.

Abbott Laboratories is facing a near-term setback because management cut full-year comparable sales growth to about 6% and now expects roughly 20% EP growth in 4Q versus prior expectations of about 25%, driven by slower Amulet-related orders and broader LAA weakness as customers wait for Amulet 360. Diabetes is also a headwind, while a roughly 1-point FX drag, greater-than-expected competition, and macro pressure further cloud the margin and revenue outlook, leading to lower 2027 revenue and EPS estimates. Even with a strong portfolio and product launches such as Volt PFA, TactiFlex Duo, and Libre Duo, the company’s outlook is pressured by temporary but material execution and demand issues, with 2026 revised revenue of $49.994 billion and adj. EPS of $5.52.